GLP1R and diabetes mellitus: No data are available about the most recent antidiabetic treatments with sodium–glucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist because the study enrolment period was before the publication of the most recent guidelines for DM management [46].